N-(n-Butyl)deoxygalactonojirimycin
Lucerastat is a selective α-D-galactosidase inhibitor. It can prevent glucosylceramide biosynthesis both in vitro and in mouse models of lysosome storage disorders through inhibiting the ceramide-specific glucosyltransferase, UDP-glucose ceramide glucosyltransferase (IC50 = 41.4 µM) but it does not affect α-glucosidase I and II or β-glucocerebrosidase (IC50s > 1 mM). In Jul 2016, Actelion completed phase Ib trial in Fabry's disease,but no development was reported for the treatment of Lipid metabolism disorders.
| Supplier | BOC Sciences |
|---|---|
| Product # | 141206-42-0 |
| Pricing | Inquire |
| Cas | 141206-42-0 |
| Molecular Weight | 219.28 |
| Molecular Formula | C10H21NO4 |
| Canonical SMILES | OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@H]1O |